ATI 2001

Drug Profile

ATI 2001

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator ARYx Therapeutics
  • Class Antiarrhythmics; Benzofurans
  • Mechanism of Action Beta-adrenergic receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 10 Nov 2006 Discontinued - Preclinical for Arrhythmias in USA (unspecified route)
  • 03 Nov 2003 A preclinical study has been added to the Arrhythmias pharmacodynamics section
  • 16 Jan 1996 Preclinical development for Arrhythmias in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top